TRU Precious Metals Corp. is pleased to announce the acquisition of 14 mineral claims at its Golden Rose Project in Central Newfoundland.Read full newsRead More
Alcoa Corporation (NYSE:NYSE:AA) Q4 2022 Earnings Conference Call January 18, 2023 5:00 PM ETCompany ParticipantsJames Dwyer - Vice President, Investor RelationsRoy Harvey - President and...Read full newsRead More
The following slide deck was published by Alcoa Corporation in conjunction with their 2022 Q4 earnings call.Read full newsRead More
Teva Pharmaceutical's undoing was its $40.5B deal to acquire Allergan's generic drug business in 2015. Read why TEVA's 56% run in the stock price makes it a Sell.Read full newsRead More
Kinder Morgan, Inc. (NYSE:NYSE:KMI) Q4 2022 Results Conference Call January 18, 2023 4:30 PM ETCompany ParticipantsRich Kinder - Executive ChairmanSteve Kean - CEOKim Dang - PresidentTom...Read full newsRead More
Alpha Metallurgical Resources represents a very favorable risk-reward at ~1.1X EV/EBITDA. Click here to read why AMR stock is a Buy.Read full newsRead More
CenterPoint Energy is positioned to deliver reasonably strong growth through the end of the decade. See why CNP looks a bit expensive relative to its peers.Read full newsRead More
Bristol Myers Squibb touted the launch of 9 new products in the U.S. While these products need more insurance coverage, read why I still rate BMY stock a Buy.Read full newsRead More
Relay Therapeutics discovers drugs using a novel computational approach. Though I like RLAY stock, see why I will wait for a correction before taking a call.Read full newsRead More
I see very bright earnings prospects for Enterprise Products Partners L.P. both in the near term and also long term. Click here to see my take on EPD stock.Read full newsRead More
Bentley Systems stands out by offering comprehensive solutions that cover the entire lifecycle of an infrastructure project. Read more to see why BSY is a Buy.Read full newsRead More
CNX Resources Corp. is an independent E&P focused on the production of natural gas in the Appalachian region. Read why we think CNX stock looks incredibly cheap.Read full newsRead More
Sportradar is set to capitalize on sports betting legalization and tailwinds in 2023. Read more to see my 5 reasons to invest in SRAD stock in 2023.Read full newsRead More
New year, new investment opportunities. This month's dividend growth screener article presents ideas worth exploring further. Read more to see our picks.Read full newsRead More
BridgeBio Pharma has a lot of irons in the fire. Despite getting approvals for two products, there's hardly any revenue. Read more to see our stance on BBIO.Read full newsRead More
Since 2020, Alibaba insiders Masa Son, Jack Ma, and Joe Tsai have done nothing but sell shares. Read why I still maintain a Buy rating on BABA stock.Read full newsRead More
The war in Ukraine is the biggest land conflict in Europe since WWII. See my analysis of the implications on the economy and markets.Read full newsRead More
Exelixis is a young commercial stage biopharma that is enjoying success with its CABOMETYX. Read more to see why I consider EXEL stock a near-term buy.Read full newsRead More
Fidelity MSCI Industrials Index ETF is an interesting alternative to Industrial Select Sector SPDR ETF. Read more to see the comparison of FIDU and XLI.Read full newsRead More
The energy sector shot higher during a risk-on week. Read more to learn why we see this week's trends continuing in 2023.Read full newsRead More